Unintended consequences of reducing QT-alert overload in a computerized physician order entry system

European Journal of Clinical Pharmacology

Volumn 65, Issue 9, 2009, Pages 919-925

  Van Der Sijs, Heleen ^a   Kowlesar, Ravi ^a   Aarts, Jos ^a   Berg, Marc ^a   Vulto, Arnold ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alert override; Computer assisted drug therapy; Computerized physician order entry; Error management; Patient safety; QT prolongation

Indexed keywords

AMIODARONE; AMITRIPTYLINE; CHLORPROMAZINE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; HALOPERIDOL; INDAPAMIDE; KETANSERIN; MIANSERIN; PROMETHAZINE; SOTALOL; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DATA BASE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HIGH RISK PATIENT; HUMAN; INFORMATION PROCESSING; MALE; NETHERLANDS; PHARMACOEPIDEMIOLOGY; PREDICTION AND FORECASTING; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES;

ADULT; AGED; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MEDICAL ORDER ENTRY SYSTEMS; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TORSADES DE POINTES;

EID: 69249222833     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0654-3     Document Type: Article

References (21)

1. H Van der Sijs J Aarts A Vulto M Berg 2006 Overriding of drug safety alerts in computerized physician order entry J Am Med Inform Assoc 13 138 147
2. EN Van Roon S Flikweert M le Comte, et al. 2005 Clinical relevance of drug-drug interactions: a structured assessment procedure Drug Safety 28 1131 1139
3. st). Pharm Weekbl 142(17):35
4. Van Roon EN, Langendijk PNJ, le Comte M (2006) QT-verlengers, WFG en interacties: the continuing story. (QT-prolonging drugs, the Working Group on Pharmacotherapy and Drug Information and drug-drug interactions: the continuing story.) Pharm Weekbl 141(20):703
5. SM Al-Khatib NMA LaPointe JM Kramer RM Califf 2003 What clinicians should know about the QT interval J Am Med Assoc 289 2120 2127
6. European Medicines Agency (2005) ICH topic E 14-note for guidance on the clinical evaluation of QT/QTc interval prolongation an proarrhytmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04). EMEA, London
7. ME Anderson SA Al-Khatib DM Roden RM Califf 2002 Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management Am Heart J 144 769 781
8. Meijer CFM, Van den Oever FJ, Schouten JP (2006) Interacties tussen QT-verlengende geneesmiddelen. Actie slechts bij enkele geneesmiddelen nodig (Interactions between QT-prolonging drugs. Action only necessary for a few drugs). Pharm Weekbl 141(4):143-144
9. F De Ponti E Poluzzi N Montanaro 2001 Organising evidence on QT prolongation and occurrence of Torsade de Pointes with non-antiarrhythmic drugs: a call for consensus Eur J Clin Pharmacol 57 185 209
10. F De Ponti E Poluzzi N Montanaro 2000 QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience Eur J Clin Pharmacol 56 1 18
11. Meijer CFM, Van den Oever FJ, Schouten JP (2006) Klinische relevantie QT-interacties goed in te schatten per patient. Inhoudelijke beoordeling van onze adviezen gewenst. (Clinical relevance of QT-interactions can be assessed per patient. Review of recommendations with respect to content is desired). Pharm Weekbl 141(10):330
12. Croonen H (2006) Wegklikken, net als bij Windows. Klinische relevantie QT-interacties goed in te schatten per patient. (Clicking away, just as in Windows. Clinical relevance of QT-interactions can be assessed per patient). Pharm Weekbl 141(7):239-240
13. Langendijk P, van Roon EN, de Bruin ML et al (2006) Interactie tussen QT-verlengende geneesmiddelen. Interactietekst kan wellicht concreter. (Interaction between QT-prolonging drugs. Alert text can perhaps be more concrete). Pharm Weekbl 141(8):258
14. Langendijk P, de Bruin M, Tan H, Wilde A (2007) Bewaking van QT-tijdverlenging. Hoe groot het risico is en hoe apothekers het kunnen beperken (Checking QT-prolongation. The risk and how pharmacists can reduce it). Pharm Weekbl 142(17):30-33
15. Arizona CERT (2009) Arizona Center for Education and Research on Therapeutics home page. http://www.torsades.org. Accessed February 7th 2009.
16. MD Kalmeijer W Holtzer R van Dongen H-J Guchelaar 2003 Implementation of a computerized physician order entry system at the Academic Medical Centre in Amsterdam Pharm World Sci 25 3 88 93
17. Van der Sijs H, Kowlesar R, Klootwijk APJ, Nelwan SP, Vulto AG, Van Gelder T (2008) Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol 67:347-354
18. H Van der Sijs J Aarts T Van Gelder M Berg A Vulto 2008 Turning off frequently overridden drug alerts: limited opportunities for doing it safely J Am Med Inform Assoc 15 439 448
19. DW Bates GJ Kuperman S Wang T Gandhi A Kittler L Volk C Spurr R Khorasani M Tanasijevic M Tanasijevic B Middleton 2003 Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality J Am Med Inform Assoc 10 523 530
20. J Molnar F Zhang J Weiss FA Ehlert JE Rosenthal 1996 Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events J Am Coll Cardiol 27 76 83
21. B Darpo M Agin DJ Kazierad G Layton G Muirhead P Gray DK Jorkasky 2006 Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 46 598 612